Literature DB >> 21875456

Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services.

R J Harris1, V D Hope, A Morongiu, M Hickman, F Ncube, D DE Angelis.   

Abstract

In developed countries the majority of hepatitis C virus (HCV) infections occur in injecting drug users (IDUs) with prevalence in IDUs often high, but with wide geographical differences within countries. Estimates of local prevalence are needed for planning services for IDUs, but it is not practical to conduct HCV seroprevalence surveys in all areas. In this study survey data from IDUs attending specialist services were collected in 52/149 sites in England between 2006 and 2008. Spatially correlated random-effects models were used to estimate HCV prevalence for all sites, using auxiliary data to aid prediction. Estimates ranged from 14% to 82%, with larger cities, London and the North West having the highest HCV prevalence. The methods used generated robust estimates for each area, with a well-identified spatial pattern that improved predictions. Such models may be of use in other areas of study where surveillance data are sparse.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21875456     DOI: 10.1017/S0950268811001634

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  6 in total

1.  Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic.

Authors:  Des Crowley; Walter Cullen; Eamon Laird; John S Lambert; Tina Mc Hugh; Carol Murphy; Marie Claire Van Hout
Journal:  J Transl Int Med       Date:  2017-06-30

2.  'HepCheck Dublin': an intensified hepatitis C screening programme in a homeless population demonstrates the need for alternative models of care.

Authors:  John S Lambert; Ross Murtagh; Dee Menezes; Austin O'Carroll; Carol Murphy; Walter Cullen; Tina McHugh; Gordana Avramovic; Willard Tinago; Marie Claire Van Hout
Journal:  BMC Infect Dis       Date:  2019-02-07       Impact factor: 3.090

3.  Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).

Authors:  Matthew Hickman; John F Dillon; Lawrie Elliott; Daniela De Angelis; Peter Vickerman; Graham Foster; Peter Donnan; Ann Eriksen; Paul Flowers; David Goldberg; William Hollingworth; Samreen Ijaz; David Liddell; Sema Mandal; Natasha Martin; Lewis J Z Beer; Kate Drysdale; Hannah Fraser; Rachel Glass; Lesley Graham; Rory N Gunson; Emma Hamilton; Helen Harris; Magdalena Harris; Ross Harris; Ellen Heinsbroek; Vivian Hope; Jeremy Horwood; Sarah Karen Inglis; Hamish Innes; Athene Lane; Jade Meadows; Andrew McAuley; Chris Metcalfe; Stephanie Migchelsen; Alex Murray; Gareth Myring; Norah E Palmateer; Anne Presanis; Andrew Radley; Mary Ramsay; Pantelis Samartsidis; Ruth Simmons; Katy Sinka; Gabriele Vojt; Zoe Ward; David Whiteley; Alan Yeung; Sharon J Hutchinson
Journal:  BMJ Open       Date:  2019-09-24       Impact factor: 2.692

4.  HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.

Authors:  N K Martin; G R Foster; J Vilar; S Ryder; M E Cramp; F Gordon; J F Dillon; N Craine; H Busse; A Clements; S J Hutchinson; A Ustianowski; M Ramsay; D J Goldberg; W Irving; V Hope; D De Angelis; M Lyons; P Vickerman; M Hickman
Journal:  J Viral Hepat       Date:  2014-10-07       Impact factor: 3.728

5.  New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England.

Authors:  R J Harris; N K Martin; E Rand; S Mandal; D Mutimer; P Vickerman; M E Ramsay; D De Angelis; M Hickman; H E Harris
Journal:  J Viral Hepat       Date:  2016-03-29       Impact factor: 3.728

6.  Reaching mEthadone users Attending Community pHarmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV).

Authors:  Christopher Byrne; Andrew Radley; Sarah Karen Inglis; Lewis J Z Beer; Nicki Palmer; Minh Duc Pham; Brendan Healy; Joseph S Doyle; Peter Donnan; John F Dillon
Journal:  BMJ Open       Date:  2020-08-30       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.